地中海国家中强基化病的状况
Dalal A Shuqair1, AbdelRahman Zueter2, Nawal Hijjawi2
1Department of Basic Medical Sciences, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa 13133, Jordan.
Journal of infection in developing countries
|July 28, 2025
概括
斯特朗基洛伊迪病是一种严重的寄生虫感染,在地中海国家仍然被忽视. 提高认识对于医疗保健提供者来说至关重要,以识别从特有地区返回的携带者.
科学领域:
- 医学寄生虫学 医学寄生虫学
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 斯特朗基洛伊迪病是一种具有全球意义的寄生虫感染,特别是在热带/亚热带地区.
- 感染可能在几十年内处于休眠状态,并在免疫抑制下重新激活.
- 据估计,全球约有6亿人长期感染Strongyloides stercoralis.
研究的目的:
- 审查地中海国家中Strongyloides stercoralis和strongyloidiasis的现状.
- 为了强调该地区这种感染被忽视的性质.
- 强调需要提高医疗保健提供者的意识.
主要方法:
- 采用了叙事审查方法.
- 在主要的科学数据库 (PubMed,Science Direct,Google Scholar,MEDLINE) 中进行了搜索.
- 包括过去十年中关于地中海国家的研究和案例报告.
主要成果:
- 在许多地中海国家,强基化病的认识不足.
- 在非热带地区报告了零星病例,慢性无症状感染很常见.
- 审查强调了从特有地区进口病例的可能性.
结论:
- 斯特朗基洛伊迪病是地中海地区的一个被忽视的热带疾病.
- 医疗保健提供者需要提高对从特有地区返回的潜在载体的认识.
- 及时诊断和管理对于预防高感染综合征至关重要.
相关概念视频
Fungal Phylum Microsporidia
122
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
122
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
203
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
203
Drugs for Treatment of Constipation-Predominant IBS
336
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
336
Drugs for Treatment of Diarrhea-Predominant IBS
299
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
299
Diseases of the Liver and Gallbladder
1.0K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
405
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
405


